CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Candida - oral - Management
Basis for recommendation
Follow-up recommendations for people with oral candidal infection are pragmatic, and reflect what CKS considers to be good clinical practice.
- Oral candidiasis is unusual in otherwise healthy people, but anecdotal and extrapolated evidence indicates that treatment is effective, and follow up is rarely necessary for mild, localized candidal infection. However, it is reasonable to follow up extensive or severe candidiasis to ensure the infection has cleared and complications have not developed.
- There are no clinical data on which to base decisions if initial treatment is not fully effective. However, extending treatment or switching to nystatin (which may be effective against resistant organisms) or oral fluconazole (which has a systemic effect) are reasonable options before expert advice or referral are sought [Samaranayake et al, 2009].
© NHS Institute for Innovation and Improvement